Multiple myeloma trials in China

In China 203 Also abroad 703

203 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
Where
Guangzhou
People
200
Run by
Zhujiang Hospital
See details and how to joinNCT05686447
Phase 1/2Taking people
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Where
Tianjin
Age
18 years and over
People
90
Run by
Tianjin Medical University General Hospital
See details and how to joinNCT06911710
Phase 1/2Taking people
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Where
Chengdu
Age
18 years to 75 years
People
144
Run by
Chengdu Zenitar Biomedical Technology Co., Ltd
See details and how to joinNCT06484829
Phase 3Not yet taking people in China
A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
Where
Shanghai
Age
18 years and over
People
386
Run by
Shanghai Henlius Biotech
See details and how to joinNCT06895512
Phase 2/3Taking people
KPD Consolidation After ASCT in NDMM Patients
Where
Beijing, Shanghai
Age
18 years and over
People
202
Run by
Peking University People's Hospital
See details and how to joinNCT06879379
Phase 1/2Taking people
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Where
Kunming
Age
18 years to 75 years
People
80
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT04271644
Phase 1/2Taking people
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Where
Kunming
Age
18 years to 75 years
People
80
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT04776330
Phase 2Taking people
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Where
Xiamen
Age
18 years and over
People
25
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06158412
Early phase 1Taking people
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Where
Wuhan
Age
18 years and over
People
24
Run by
Chunrui Li
See details and how to joinNCT06791681
Phase 1/2Not yet taking people in China
A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
Where
Wuhan, Xianning, Zhengzhou
Age
18 years to 65 years
People
42
Run by
Fuling Zhou
See details and how to joinNCT06799676
No phaseTaking people
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
Where
Taiyuan
People
45
Run by
Shanxi Bethune Hospital
See details and how to joinNCT06783816
Phase 1Taking people
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Where
Guangzhou
Age
18 years to 75 years
People
60
Run by
The Third Affiliated Hospital of Southern Medical University
See details and how to joinNCT06758713
Phase 1/2Taking people
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Where
Xuzhou
Age
18 years to 70 years
People
20
Run by
Xuzhou Medical University
See details and how to joinNCT06759181
No phaseTaking people
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
Where
Guanzhou
Age
45 years and over
People
2,990
Run by
Zhujiang Hospital
See details and how to joinNCT06690593
Phase 1/2Taking people
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Nanchang, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xian, Xuzhou
Age
18 years and over
People
116 worldwide
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT06083207
Early phase 1Taking people
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Where
Shanghai
Age
18 years to 75 years
People
12
Run by
Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT06732232
Early phase 1Taking people
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Where
Shanghai
Age
18 years and over
People
24
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT06718270
Phase 1Taking people
A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
Where
Chengdu, Shanghai
Age
18 years to 75 years
People
136
Run by
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT06700395
No phaseTaking people
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Where
Beijing, Harbin
Age
18 years and over
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT06697483
No phaseTaking people
Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
Where
Suzhou
Age
18 years and over
People
50
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06682156
Phase 1Taking people
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Beijing, Hangzhou, Xi’an
Age
18 years to 75 years
People
58
Run by
Zhejiang University
See details and how to joinNCT06644118
Phase 1/2Taking people
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Where
Beijing
Age
18 years and over
People
48
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT05299424
Phase 2Taking people
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Where
Xiamen
Age
18 years to 80 years
People
5
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06581640
No phaseTaking people
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
Where
Guanzhou
Age
45 years and over
People
300
Run by
Zhujiang Hospital
See details and how to joinNCT06539832
No phaseNot yet taking people in China
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
Where
Shanghai
Age
18 years to 75 years
People
18
Run by
RenJi Hospital
See details and how to joinNCT06594211